Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

1. Arias-Martinez, A.
2. Martínez de Castro, E.
3. Gallego, J.
4. Arrazubi, V.
5. Custodio, A.
6. Fernández Montes, A.
7. Diez, M.
8. Hernandez, R.
9. Limón, M.L.
10. Cano, J.M.
11. Vidal-Tocino, R.
12. Macias, I.
13. Visa, L.
14. Martin Richard, M.
15. Sauri, T.
16. Hierro, C.
17. Gil, M.
18. Cerda, P.
19. Martínez Moreno, E.
20. Martínez Lago, N.
21. Mérida-García, A.J.
22. Gómez González, L.
23. García Navalón, F.J.
24. Ruiz Martín, M.
25. Marín, G.
26. López-López, F.
27. Ruperez Blanco, A.B.
28. Fernández, A.F.
29. Jimenez-Fonseca, P.
30. Carmona-Bayonas, A.
31. Alvarez-Manceñido, F.
32. Show all authors +

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1007/S12094-024-03388-6 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus